Efficacy of sequential adjuvant chemolipiodolization on hepatocellular carcinoma: Phase II, open labeled, and historical controlled study

Efficacy of sequential adjuvant chemolipiodolization on hepatocellular carcinoma: Phase II, open labeled, and historical controlled study - Efficacy of sequential adjuvant chemolipiodolization on hepatocellular carcinoma: Phase II, open labeled, and historical controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026633

Enrollment

Registered

2017-04-01

Start date

2012-11-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Sequential chemolipiodolization (at 3,6,and 12 month after hepatectomy)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Performance status 0~2 at 3 month after hepatectomy 2)Child Pugh A/B at 3 month after hepatectomy 3)Well maintained bone marrow and renal function at 3 month after hepatectomy /WBC count;1,000~12,0000/mm3 /Platelet count;>=50,000/mm3 /Hemoglobin;>=10.0g/dL /Serum creatinine level;<=1.5mg/dL 4)Written informed concent

Exclusion criteria

Exclusion criteria: 1)History of iodine-based contrast enhancement allergy 2)History of another malignant disease within the past 5 years

Design outcomes

Primary

Measure	Time frame
Recurrence free survival at two years after hepatectomy	—

Secondary

Measure	Time frame
Liver function Recurrence pattern Recurrence free survival at five years after hepatectomy Overall survival at two and five years after hepatectomy	—

Countries

Japan

Contacts

Public ContactMasaki Ueno

Wakayama Medical University Second Department of Surgery

ma@wakayama-med.ac.jp073-441-0613

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026